5711-41-1

Basic information

• Product Name: 3-(4-METHOXYBENZOYL)ACRYLIC ACID
• Synonyms: (E)-4-(4-METHOXY-PHENYL)-4-OXO-BUT-2-ENOIC ACID;AKOS 90960;3-(4-METHOXYBENZOYL)ACRYLIC ACID;TRANS-3-(4-METHOXYBENZOYL)ACRYLIC ACID;2-Butenoic acid, 4-(4-methoxyphenyl)-4-oxo-;Nsc25331;4-(4-Methoxyphenyl)-4-oxobut-2-enoic acid
• CAS NO: 5711-41-1
• Molecular Formula: C₁₁H₁₀O₄
• Molecular Weight: 206.19
• Product Categories: Aromatic Cinnamic Acids, Esters and Derivatives;C11 to C12;Carbonyl Compounds;Carboxylic Acids;Building Blocks;C11 to C12;Carbonyl Compounds;Carboxylic Acids;Chemical Synthesis;Organic Building Blocks
• Mol File: 5711-41-1.mol
• Article Data: 8

Chemical Properties

• Melting Point: 132-136 °C(lit.)
• Boiling Point: 389.3oC at 760 mmHg
• Flash Point: 155.2oC
• Appearance: /
• Density: 1.24g/cm3
• Vapor Pressure: 9.32E-07mmHg at 25°C
• Refractive Index: 1.561
• PKA: 3.25±0.10(Predicted)
• BRN: 474529
• CAS DataBase Reference: 3-(4-METHOXYBENZOYL)ACRYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-METHOXYBENZOYL)ACRYLIC ACID(5711-41-1)
• EPA Substance Registry System: 3-(4-METHOXYBENZOYL)ACRYLIC ACID(5711-41-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• RTECS: AT2250000
• Hazardous Substances Data: 5711-41-1(Hazardous Substances Data)

Usage

General Description

3-(4-Methoxybenzoyl)acrylic acid is a chemical compound with the molecular formula C11H10O4. It is a derivative of acrylic acid and features a 4-methoxybenzoyl group attached to the acrylic acid backbone. 3-(4-METHOXYBENZOYL)ACRYLIC ACID is commonly used in the synthesis of various organic compounds and pharmaceuticals due to its ability to undergo various chemical reactions. It also possesses potential biological activity, making it a subject of interest in medicinal chemistry research. Additionally, 3-(4-Methoxybenzoyl)acrylic acid has applications in the field of materials science, particularly in the development of functional polymers and coatings.

InChI:InChI=1/C11H10O4/c1-15-9-4-2-8(3-5-9)10(12)6-7-11(13)14/h2-7H,1H3,(H,13,14)/b7-6+

Upstream product

• 24849-51-2 3-bromo-4-(4-methoxyphenyl)-4-oxobutanoic acid 
• 127-09-3 sodium acetate 
• 64-19-7 acetic acid 
• 127427-28-5 4-(4-methoxy-phenyl)-4-oxo-crotonic acid ethyl ester 
• 17615-10-0 methyl 4-(4-methoxyphenyl)-4-oxobut-2-enoate 
• 91142-97-1 4-(p-methoxyphenyl)-3-butenoic acid 
• 7553-56-2 iodine 
• 298-12-4 Glyoxilic acid 
• 100-06-1 1-(4-methoxyphenyl)ethanone 
• 2632-13-5 2-Bromo-4'-methoxyacetophenone 
• 128934-96-3 2-hydroxy-4-(4-methoxyphenyl)but-3-enoic acid 
• 3153-44-4 4-(4-methoxy-phenyl)-4-oxo-butyric acid 
• 5447-74-5 methyl 3-(4-methoxybenzoyl)propionate 
• 7647-01-0 hydrogenchloride 

Downstream Products

• 63639-60-1 2-hydroxy-4-(4-methoxy-phenyl)-4-oxo-butyric acid 
• 298-12-4 Glyoxilic acid 
• 100-06-1 1-(4-methoxyphenyl)ethanone 
• 106422-25-7 3-(4-methoxy-phenyl)-5-oxo-cyclohex-3-enecarboxylic acid 
• 132590-32-0 5-Bromo-1-(4-methoxy-benzoyl)-benzo[f]chromen-3-one 
• 132590-30-8 1,2-Dibromo-1-(4-methoxy-benzoyl)-1,2-dihydro-benzo[f]chromen-3-one 
• 132590-26-2 1-(4-Methoxy-benzoyl)-2-[1-phenyl-meth-(Z)-ylidene]-1,2-dihydro-benzo[f]chromen-3-one 
• 132590-38-6 (4-Methoxy-phenyl)-[11-(4-methoxy-phenyl)-9-phenyl-8,12-dihydro-11H-7-oxa-8-aza-benzo[a]anthracen-12-yl]-methanone 
• 132590-40-0 2-Benzoyl-1,3-bis-(4-methoxy-phenyl)-3a,11c-dihydro-3H-5-oxa-cyclopenta[c]phenanthren-4-one 
• 132590-34-2 1-(4-Methoxy-benzoyl)-2-[1-(4-methoxy-phenyl)-3-oxo-3-phenyl-propyl]-1,2-dihydro-benzo[f]chromen-3-one 
• 127574-08-7 6,9,9a,9b-tetrahydro-8-(p-methoxyphenyl)-1-methyl-3-phenyl-3H-pyrazolo<3,4-c>pyridazino<4,3-e>pyridazine 
• 127574-11-2 3,9,9a,9b-tetrahydro-8-(4-methoxyphenyl)-1-methyl-3-phenyl-6H-pyrazolo<3,4-c>pyridazino-<4,3-e>pyridazine-6-acetate 
• 127574-12-3 6,9b-dihydro-8-(4-methoxyphenyl)-9-<(4-methoxyphenyl)methyl>-1-methyl-3-phenyl-3H-pyrazolo-<3,4-c>pyridazino<4,3-e>pyridazine 
• 127574-14-5 6,9,9a,9b-tetrahydro-8,9-bis(4-methoxyphenyl)-1-methyl-3-phenyl-3H-pyrazolo<3,4-c>pyridazino<4,3-e>pyridazine 

Relevant articles and documents

Synthesis of chiral γ-lactones via a RuPHOX-Ru catalyzed asymmetric hydrogenation of aroylacrylic acids

An asymmetric hydrogenation of aroylacrylic acids catalyzed by RuPHOX-Ru catalyst has been developed, affording the corresponding chiral γ-lactones in high yields and with up to 93% ee. The methodology has the advantage of utilizing easily accessible substrates and has therefore expand the scope of the resulting chiral γ-lactones. Furthermore, high catalytic efficiency was achieved in that the reduction of both the C[dbnd]C and C[dbnd]O double bonds was achieved in one step. The current work provides an alternative and convenient pathway for the synthesis of a wide range of chiral γ-lactones.

Synthesis and biological evaluations of 1,2-diaryl pyrroles as analogues of combretastatin A-4

A series of novel 1,2-diaryl pyrroles as analogues of combretastatin A-4 (CA-4, 1a) were synthesized and evaluated for their antitumour potential against three cancer cell lines. Most compounds exhibited growth inhibition against all of the cancer cell lines. Compound 7q not only exhibited prominent antitumour efficacy with IC50 values of 0.390 μm in SGC-7901, 0.070 μm in HT-1080 and 0.045 μm in KB cell lines but also showed low activity with IC50 values of 30.08 μm in normal L929 cell line. Moreover, compound 7q inhibited tubulin polymerization into microtubules and caused microtubule destabilization. A molecular docking study of 7q was performed to determine its binding mode at the colchicine site in the tubulin dimer. 1,2-Diaryl pyrroles as combretastatin A-4 analogues were synthesized and evaluated for anti-proliferative activities. Compound 7q exhibited antitubulin activity.

Synthesis and evaluation of anticancer activity of some novel 6-aryl-2-(p-sulfamylphenyl)-pyridazin-3(2H)-ones

A series of novel pyridazinone derivatives bearing benzenesulfonamide moiety (2a-h) has been synthesized by the condensation of appropriate aroylacrylic acid and 4-hydrazinobenzenesulfonamide hydrochloride in ethanol. Five derivatives (2a, 2b, 2d, 2g and 2h) were evaluated for their anticancer activity toward human cancer cell lines by the National Cancer Institute. The 2h showed remarkable activity against SR (leukemia) and NCI-H522 (non-small cell lung) with a GI50 value of less than 0.1 μM. It also displayed good activity against leukemia (CCRF-CEM, HL-60 (TB), K-562, MOLT-4, RPMI-8226), non-small cell lung cancer (NCI-H460), colon (HCT-116, HCT-15, HT29, KMI2, SW-620), CNS (SF-295), melanoma (MALME-3M, M14, MDA-MB-435 SK-MEL-5), ovarian (OVCAR-3, NCI/ADR-RES) and breast (MCF7) cancer cell lines with a GI 50 less than 1.0 μM. The acute toxicity study of 2h indicated that it is well tolerated intra-peritoneally (400 mg/kg) by athymic nude mice. The 2h may possibly be used as lead compound for developing new anticancer agents.